Published in Blood on January 15, 1993
Tissue distribution of the multidrug resistance protein. Am J Pathol (1996) 1.84
A theoretical quantitative model for evolution of cancer chemotherapy resistance. Biol Direct (2010) 1.69
Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res (2012) 1.19
Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer (1995) 1.14
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget (2013) 1.10
Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol (2013) 0.96
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood (2005) 0.95
A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood (2011) 0.94
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev (2013) 0.92
New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues. Am J Pathol (1994) 0.92
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol (2013) 0.89
PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells. Br J Cancer (2010) 0.85
Properties and identification of cancer stem cells: a changing insight into intractable cancer. Surg Today (2010) 0.80
The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia. Leuk Res Treatment (2012) 0.80
Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line. Br J Cancer (1999) 0.80
Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 0.79
CYT997 causes apoptosis in human multiple myeloma. Invest New Drugs (2009) 0.79
Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter? Am J Cancer Res (2016) 0.78
P-glycoprotein positive, drug resistant invasive lymphoepithelial thymoma: treatment response to chemotherapy with cyclosporin and quinine. J Clin Pathol (1995) 0.76
The treatment of multiple myeloma--an important MRC trial. Br J Cancer (1994) 0.76
Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Clin Epigenetics (2017) 0.75
The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo. Oncotarget (2016) 0.75
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med (2001) 11.73
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer (1975) 10.04
Primary bioassay of human tumor stem cells. Science (1977) 9.69
A new type of synthetic peptide library for identifying ligand-binding activity. Nature (1991) 7.81
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 7.78
Freeze-etching nomenclature. Science (1975) 7.41
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med (1978) 5.78
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med (1998) 5.74
High speed scintillation autoradiography. Science (1975) 5.15
Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell (2001) 4.78
The ultrastructure of the nexus. A correlated thin-section and freeze-cleave study. J Cell Biol (1970) 4.48
Membrane ultrastructure at mammalian intercellular junctions. Prog Biophys Mol Biol (1973) 4.30
Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood (1999) 4.13
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res (2001) 4.05
Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest (1999) 3.60
Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science (2002) 3.46
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest (1999) 3.30
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
Raised serum levels of tumour necrosis factor in parasitic infections. Lancet (1986) 3.23
Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med (1974) 2.97
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol (1989) 2.89
The drug resistance-related protein LRP is the human major vault protein. Nat Med (1995) 2.78
Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res (1998) 2.72
The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A (1994) 2.71
Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res (1997) 2.67
Inside-out red cell membrane vesicles: preparation and purification. Science (1970) 2.61
The application of freeze-cleaving technics to studies on red blood cell fine structure. Blood (1967) 2.58
Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A (1994) 2.52
Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res (1999) 2.50
Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (1996) 2.35
The calcium-binding protein cell division cycle 31 of Saccharomyces cerevisiae is a component of the half bridge of the spindle pole body. J Cell Biol (1993) 2.28
Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest (1996) 2.26
Primary bioassay of human myeloma stem cells. J Clin Invest (1977) 2.25
Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood (1990) 2.24
Direct cloning of human ovarian carcinoma cells in agar. Cancer Res (1978) 2.24
Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest (1970) 2.21
B-cell neoplasia in man. Lancet (1974) 2.11
Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection. Nat Genet (1994) 2.09
Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med (1996) 2.00
Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res (1993) 1.99
The Cdc31p-binding protein Kar1p is a component of the half bridge of the yeast spindle pole body. J Cell Biol (1995) 1.95
Prevention of doxorubicin-induced hair loss with scalp hypothermia. N Engl J Med (1979) 1.94
Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol (2001) 1.94
Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med (1998) 1.84
Tissue distribution of the multidrug resistance protein. Am J Pathol (1996) 1.84
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A (2000) 1.83
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology (1997) 1.79
The structure and function of intercellular junctions in cancer. Adv Cancer Res (1976) 1.79
Arizona Telemedicine Program: implementing a statewide health care network. J Am Med Inform Assoc (1998) 1.78
Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene (2000) 1.75
Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res (1986) 1.75
"Sandwich" solid phase radioimmunoassay for the quantitative deterimination of human immunoglobulins. J Immunol (1969) 1.74
Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem (1998) 1.74
Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res (1994) 1.73
Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res (1999) 1.72
Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma. N Engl J Med (1990) 1.72
Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. Blood (1992) 1.69
Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol (1997) 1.68
The freeze-cleave approach to the ultrastructure of frozen tissues. Cryobiology (1970) 1.66
Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia (2003) 1.65
The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat Genet (2000) 1.64
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol (1991) 1.64
The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium. J Immunol (1991) 1.63
Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol (2000) 1.62
Reversal of drug-resistance in multiple myeloma with verapamil. Br J Haematol (1988) 1.60
MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A (1999) 1.59
Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229. J Clin Oncol (1996) 1.57
Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood (1988) 1.55
P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood (1994) 1.55
New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res (1999) 1.54
Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. Blood (1998) 1.52
Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int (2008) 1.52
Effect of host-cell interactions on clonogenic carcinoma cells in human malignant effusions. Br J Cancer (1980) 1.52
Polyamines as markers of response and disease activity in cancer chemotherapy. Cancer Res (1977) 1.52
Dose response evaluation of adriamycin in human neoplasia. Cancer (1977) 1.51
Preparation of permanent slides of intact soft-agar colony cultures of hematopoietic and tumor stem cells. Cancer Res (1979) 1.51
Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res (1991) 1.50
Hypercalcemia due to hard water used for home hemodialysis. South Med J (1992) 1.50
Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology (2006) 1.49
The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG. Hum Mol Genet (2000) 1.48
Evidence that leukocyte function-associated antigen-1 is involved in recirculation and homing of human lymphocytes via high endothelial venules. J Immunol (1988) 1.47
Use of telepathology for routine surgical pathology review in a test bed in the Department of Veterans Affairs. Telemed J (1997) 1.46
Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst (1999) 1.46
A cytotoxic analysis of antiseptic medication on skin substitutes and autograft. Br J Dermatol (2007) 1.45
The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J Bone Miner Res (2001) 1.44
Telepathology and the networking of pathology diagnostic services. Arch Pathol Lab Med (1987) 1.43
Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res (1988) 1.43
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol (1998) 1.42
Myeloperoxidase deficiency. Immunologic study of a genetic leukocyte defect. N Engl J Med (1970) 1.41
Routine surgical telepathology in the Department of Veterans Affairs: experience-related improvements in pathologist performance in 2200 cases. Telemed J (1999) 1.41
Prognostic correlation of plasma cell acid phosphatase and beta-glucuronidase in multiple myeloma: a Southwest Oncology Group study. Blood (1991) 1.40
Immunology of the lower respiratory tract. II. The plaque-forming response of canine lymphoid tissues to sheep erythrocytes after intrapulmonary or intravenous immunization. J Clin Invest (1974) 1.39
Unimpaired immune functions after laparoscopic cholecystectomy. Surgery (1994) 1.39